Sunday 18 October 2026
Export ARTV’s income statement to Excel — free account
Artiva Biotherapeutics, Inc.
ARTV Healthcare Biotechnology
Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023. In the quarter to June 2026, EPS grew 27.6% and free cash flow grew 13.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
5.85
0.21
−3.47%
Follow ARTV
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 9.68 | 1.47 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 17.31 | 11.55 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 81 | 89 | 104 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.41 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | 33 | 0 | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | 100.00 | 100.00 | — | |||||
| EBT | — | — | — | — | — | — | — | (29) | (65) | (84) | |||||
| EBT margin, % | — | — | — | — | — | — | — | (85.54) | (26,045.02) | 0.00 | |||||
| Net income | — | — | — | — | — | — | — | (29) | (65) | (84) | |||||
| Depreciation | — | — | — | — | — | — | — | 2 | 2 | 3 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 41.72 | 0.02 | 0.00 | ||||
| Earnings | — | — | — | — | — | — | — | (35.78) | (5.81) | (3.43) | |||||
| Cash flow | — | — | — | — | — | — | — | (59.09) | (4.89) | (3.14) | |||||
| Capex | — | — | — | — | — | — | — | (4.06) | (0.06) | (0.11) | |||||
| Free cash flow | — | — | — | — | — | — | — | (63.15) | (4.94) | (3.25) | |||||
| Book value | — | — | — | — | — | — | — | (201.84) | 16.58 | 4.50 | |||||
| Shares, m | — | — | — | — | — | — | — | 1 | 11 | 24 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | 0.00 | 0.00 | — | ||||
| P/S | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| P/B | — | — | — | — | — | — | — | 0.00 | 0.61 | — | |||||
| EV/Sales | — | — | — | — | — | — | — | 0.00 | 0.00 | — | |||||
| EV/FCF | — | — | — | — | — | — | — | 0.71 | 1.29 | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (47) | (55) | (77) | ||||
| Capex | — | — | — | — | — | — | — | (3) | (1) | (3) | |||||
| Free cash flow | — | — | — | — | — | — | — | (51) | (56) | (79) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 68 | 176 | 100 | ||||
| Total debt | — | — | — | — | — | — | — | — | 0 | — | |||||
| Net debt | — | — | — | — | — | — | — | (77) | (185) | (108) | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | (162) | 187 | 110 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (41.55) | (49.26) | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (3,345.37) | (2,860.92) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (530.93) | (56.55) | |||||
Negative figures in brackets.
Fiscal years to Dec 2024 · latest quarter Mar 2024
Charts ten years each
Artiva Biotherapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| ARCT Arcturus Therapeutics Holdings Inc. | $320.3M | — (loss-making) | — (loss-making) | −89.54% (below 0%: shrinking) | n/m | −245.65% (below 0%: shrinking) | 100.00% | (863.30%) | Compare |
| AGEN Agenus Inc. | $301.7M | 2.3× | 4.1× | +34.36% (above 0%: growing) | n/m | −55.25% (below 0%: shrinking) | 100.00% | 32.72% | Compare |
| CTNM Contineum Therapeutics, Inc. | $297.2M | — (loss-making) | — | — | n/m | +26.73% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ARTV Artiva Biotherapeutics, Inc. | $296.3M | — (loss-making) | — (loss-making) | — | n/m | +13.60% (above 0%: growing) | 100.00% | 0.00% | |
| BNTC Benitec Biopharma Limited | $295.1M | — (loss-making) | — (loss-making) | −85.42% (below 0%: shrinking) | n/m | +38.90% (above 0%: growing) | 0.00% | 0.00% | Compare |
| SRZN Surrozen, Inc. | $294.7M | — (loss-making) | — (loss-making) | +408.65% (above 0%: growing) | n/m | −21.25% (below 0%: shrinking) | 100.00% | (207.40%) | Compare |
| FULC Fulcrum Therapeutics, Inc. | $280.0M | — (loss-making) | — (loss-making) | +27,018.64% (above 0%: growing) | n/m | −13.05% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| OCGN Ocugen, Inc. | $275.9M | — (loss-making) | — (loss-making) | +8.38% (above 0%: growing) | n/m | −13.42% (below 0%: shrinking) | 100.00% | (1,105.11%) | Compare |
| NAUT Nautilus Biotechnology, Inc. | $274.9M | — (loss-making) | — | — | n/m | −3.16% (below 0%: shrinking) | 92.11% | (8,296.32%) | Compare |
| Median of peers | $294.9M | — | — | +21.37% | — | −13.24% | 100.00% | (103.70%) |
Artiva Biotherapeutics, Inc. (ARTV) key facts
- Concern: Artiva Biotherapeutics, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $251,000.00, down 99.3% from fiscal 2023.
- Artiva Biotherapeutics, Inc. (ARTV) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ARTV traded at $5.85, a market capitalization of $296.3 million.
- Return on equity was −56.6% and debt-to-equity 0.00.
- Its Altman Z-score is 1.27 (distress zone) for fiscal 2024.